Michael G McCully retweeted
We need a lot more Dr. Jessica Steiers to pull a body of evidence together like this
@unbiasedscipod
theunbiasedscipod.substack.c…
nytimes.com/interactive/2025…
Michael G McCully retweeted
Dr. Anantha Shekhar spoke about the development of GATE-251, a positive allosteric modulator of the NMDA receptor to treat MDD in subjects with insomnia and anxiety in a Phase 2a study that demonstrated rapid efficacy which warrants further investigation.
Michael G McCully retweeted
In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology.
They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: drugdiscoverytrends.com/gate…
Michael G McCully retweeted
Great to see coverage in @WIRED on the link between #neuroplasticity and #depression.
Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days.
#mentalhealth
A clinical trial reveals the first evidence of how the brain restructures physically in the first month on SSRIs—and the link between neuroplasticity and depression. wired.trib.al/hAlIkic
Michael G McCully retweeted
Nice @TheAtlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism
A new generation of psychedelics could offer mental-health benefits to a huge number of people.
The secret: no trips, highs, or hallucinations, @raf_ideas writes: theatlantic.com/health/archi…
Michael G McCully retweeted
Our lead program, zelquistinel, was included in a recent review paper from @UTHealthHouston on GABA-glutamate targeted drugs:
mdpi.com/1424-8247/16/11/157…
"Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!
Michael G McCully retweeted
🌍 Today we celebrate mental health around the world—because every mind matters. 💚 Let's foster understanding, empathy, and support for one another. 🤝 #WorldMentalHealthDay #MentalHealthMatters 🌍
Michael G McCully retweeted
.@EliLillyandCo's acquisition of @VersanisBio is a quintessential example of how a dormant, unappreciated, or non-strategic asset stalled in a pharma pipeline (in this instance from @NovartisScience) can be given new life by a dedicated management and investor team (more...)
Michael G McCully retweeted
In more than a third of patients with major depression, treatment with antidepressant drugs fails to control symptoms.
Read the full ELEKT-D trial Research Summary: nej.md/3ODZMPc
Michael G McCully retweeted
As part of our commitment to #mentalhealth innovation, we recently expanded our research facilities in Evanston! This renewed effort includes advancing translational EEG biomarkers supporting our '-stinel' programs that enhance synaptic function.
businesswire.com/news/home/2…
Michael G McCully retweeted
Jason Sudeikis and the rest of the #TedLasso cast visited the White House to promote mental health care: "I truly believe we should all do our best to help take care of each other. That’s my own personal belief" ti.me/40490qA
Michael G McCully retweeted
Really important paper here - critical #NMDAR mechanism understanding - #Ketamine (a channel blocker) 1.requires NMDAR activation for efficacy & synaptic function enhancement. 2.Combination with NMDAR-PAM rapastinel enhanced efficacy. (rapa also eliminates side effects of Ket…)
The underlying mechanism of ketamine in depression requires downstream NMDAR-activation. New publication from Todd Gould (gouldlab.org/)
jneurosci.org/content/early/…
Michael G McCully retweeted
Wonderful overview @PsychTimes of an important new drug candidate in #psychiatry and #CNS Dr. Anantha Shekhar & congrats @GateNeuro, Inc. on such great progress with these important new medicines and efforts toward #precisionmedicine in #Neuro ! psychiatrictimes.com/view/ne…
Gate Neuro was recently featured in @PsychTimes ! Co-founder Dr. Anantha Shekhar discusses our ongoing biomarker study with apimostinel, a rapid-acting and safe NMDAR modulator in development for acute depressive disorders. #mentalhealth #precisionmedicine
https://teapawt.net/t.co/tdqOaBdrCR
Michael G McCully retweeted
In today’s fundraising environment, it’s more helpful than ever for biotechs to be able to tell a “tight” story. This means that the value proposition is easy to communicate, understand and diligence. E.g., a “tight” story could be built around a single asset for a large...1/13
Michael G McCully retweeted
This week we announced dosing the first patient cohort in a translational EEG biomarker study of apimostinel. Press release: businesswire.com/news/home/2…
Michael G McCully retweeted
We are excited for patients with #Alzheimers given the positive lecanemab Phase 3 results that validates abeta as a disease modifying target and a pathway to potentially treating this devastating disease. Our commitment to offer transformative Alzheimer’s treatments never wavered
Michael G McCully retweeted
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis.
#NovartisNews
Michael G McCully retweeted
We are excited to officially emerge from stealth! A big thanks to our team, investors, and @abbvie and @LillyPad for their partnership in assembling our next-generation CNS portfolio. Learn more about us here: https://teapawt.net/t.co/d86FFAg5X0
#neuroscience #mentalhealth #biotech
Michael G McCully retweeted
A new study shows hate crime laws that protect gay, lesbian and transgender people may have an unexpected benefit: fewer teen suicide attempts, among kids of all sexual orientations. consumer.healthday.com/6-23-…

























